AC Immune SA (NASDAQ:ACIU) was the recipient of a large growth in short interest during the month of November. As of November 30th, there was short interest totalling 1,174,629 shares, a growth of 33.8% from the November 15th total of 877,636 shares. Based on an average daily trading volume, of 93,273 shares, the short-interest ratio is presently 12.6 days. Approximately 5.4% of the shares of the company are short sold.

AC Immune (NASDAQ ACIU) opened at $12.30 on Friday. AC Immune has a 12 month low of $6.03 and a 12 month high of $14.88.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Belpointe Asset Management LLC purchased a new position in shares of AC Immune in the 3rd quarter worth approximately $571,000. Janney Montgomery Scott LLC bought a new stake in shares of AC Immune in the 3rd quarter worth approximately $134,000. Wells Fargo & Company MN bought a new stake in shares of AC Immune in the 3rd quarter worth approximately $111,000. Finally, Goldman Sachs Group Inc. bought a new stake in shares of AC Immune in the 2nd quarter worth approximately $127,000. Hedge funds and other institutional investors own 17.12% of the company’s stock.

Separately, Zacks Investment Research upgraded AC Immune from a “sell” rating to a “hold” rating in a research note on Monday, October 16th.

TRADEMARK VIOLATION WARNING: This piece of content was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/15/ac-immune-sa-aciu-short-interest-update.html.

AC Immune Company Profile

AC Immune SA is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson’s, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms.

Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.